Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies
- Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells
- Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment
Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its groundbreaking B cell immortalization and screening platform, Kling-Select.
